Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Presented at: AACR Annual Meeting; April 10–15, 2021; Virtual. Abstract CT006 - Hughes, BGM; Munoz-Couselo, E; Mortier, L
et al.